JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB223562

Anti-PD1 antibody [EH12.2H7]

Be the first to review this product! Submit a review

|

(1 Publication)

Mouse Monoclonal PD1 antibody. Suitable for Flow Cyt and reacts with Human samples. Cited in 1 publication. Immunogen corresponding to Recombinant Fragment Protein within Human PDCD1.

View Alternative Names

CD279, PD1, PDCD1, Programmed cell death protein 1, Protein PD-1, hPD-1

2 Images
Flow Cytometry - Anti-PD1 antibody [EH12.2H7] (AB223562)
  • Flow Cyt

Unknown

Flow Cytometry - Anti-PD1 antibody [EH12.2H7] (AB223562)

Separation of human CD279 positive lymphocytes (red-filled) from neutrophil granulocytes (black-dashed) in flow cytometry analysis (surface staining) of human peripheral whole blood stained using ab223562 purified antibody at 6 μg/ml.

Flow Cytometry - Anti-PD1 antibody [EH12.2H7] (AB223562)
  • Flow Cyt

Unknown

Flow Cytometry - Anti-PD1 antibody [EH12.2H7] (AB223562)

Flow cytometry surface staining pattern of human peripheral blood stained using aab223562 at 6 μg/ml.

  • 660 APC

    APC Anti-PD1 antibody [EH12.2H7]

  • 578 PE

    PE Anti-PD1 antibody [EH12.2H7]

  • 778 PE/Cy7®

    PE/Cy7® Anti-PD1 antibody [EH12.2H7]

Key facts

Host species

Mouse

Clonality

Monoclonal

Clone number

EH12.2H7

Isotype

IgG1

Carrier free

No

Reacts with

Human

Applications

Flow Cyt

applications

Immunogen

Recombinant Fragment Protein within Human PDCD1. The exact immunogen used to generate this antibody is proprietary information.

Q15116

Epitope

Extracellular

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "FlowCyt" : {"fullname" : "Flow Cytometry", "shortname":"Flow Cyt"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Human": { "FlowCyt-species-checked": "testedAndGuaranteed", "FlowCyt-species-dilution-info": "6 µg/mL", "FlowCyt-species-notes": "<p></p>" } } }

Properties and storage information

Form
Liquid
Purification technique
Affinity purification Protein A
Purification notes
> 95 %
Storage buffer
pH: 7.4 Preservative: 0.1% Sodium azide Constituents: PBS
Shipped at conditions
Blue Ice
Appropriate short-term storage conditions
+4°C
Appropriate long-term storage conditions
+4°C

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

PD1 also known as Programmed Cell Death Protein 1 or PDCD1 is a transmembrane protein that plays a critical role in regulating immune responses. It has a mass of approximately 55 kDa. PD1 is expressed on the surface of T cells B cells and some myeloid cells. PD1's expression increases upon activation of these immune cells assisting in maintaining peripheral tolerance. Researchers often use PD1 mouse models and chimeric antibodies to explore the function of PD1 for experimental purposes. Antibodies such as anti-PD1 such as EH12.2H7 help in blocking PD1 interaction to study its role further.
Biological function summary

PD1 serves as an inhibitory receptor acting as a checkpoint in the immune system. It becomes part of an immune-suppressive complex when it binds with its ligands PD-L1 or PD-L2 which are expressed on various cell types including some tumor cells. This interaction suppresses the proliferation of T cells and cytokine production contributing to immune homeostasis. By controlling T cell activity PD1 limits autoimmunity but can also reduce the immune system's capability to attack cancer cells.

Pathways

PD1 functions in the immune checkpoint pathway a critical regulatory circuit in immune regulation. The engagement of PD1 with its ligands initiates a cascade that inhibits the function and proliferation of T cells through downstream SHP-2 phosphatase activity. This pathway frequently involves other regulatory proteins like CTLA-4 and is an important mechanism by which the body modulates immune responses. Related pathways often intersect with those involving T cell receptor signaling and contribute to the overall modulation of immune activity.

PD1 has a significant role in cancer and autoimmune disorders. PD1 expression can allow tumors to evade immune surveillance making PD1 a target for cancer therapies such as anti-PD1 antibodies which aim to block PD1 and restore T cell activity. The interaction of PD1 with cancer-related proteins like PD-L1 facilitates tumor immune evasion. In autoimmune disorders PD1's regulation of immune balance can become dysregulated leading to persistent immune activation and tissue damage. Understanding PD1 and its interaction with proteins such as PD-L1 helps in developing therapeutic strategies for both cancer and autoimmune conditions.

Product protocols

For this product, it's our understanding that no specific protocols are required. You can visit:

Target data

Inhibitory receptor on antigen activated T-cells that plays a critical role in induction and maintenance of immune tolerance to self (PubMed : 21276005, PubMed : 31754127, PubMed : 32184441, PubMed : 37208329). Delivers inhibitory signals upon binding to ligands CD274/PDCD1L1 and CD273/PDCD1LG2 (PubMed : 21276005, PubMed : 26602187). Following T-cell receptor (TCR) engagement, PDCD1 associates with TCR-CD3 in the immunological synapse and directly inhibits T-cell activation (PubMed : 32184441). Suppresses T-cell activation through the recruitment of PTPN11/SHP-2 : following ligand-binding, PDCD1 is phosphorylated within the ITSM motif, leading to the recruitment of the protein tyrosine phosphatase PTPN11/SHP-2 that mediates dephosphorylation of key TCR proximal signaling molecules, such as ZAP70, PRKCQ/PKCtheta and CD247/CD3zeta (PubMed : 32184441).. The PDCD1-mediated inhibitory pathway is exploited by tumors to attenuate anti-tumor immunity and escape destruction by the immune system, thereby facilitating tumor survival (PubMed : 28951311). The interaction with CD274/PDCD1L1 inhibits cytotoxic T lymphocytes (CTLs) effector function (PubMed : 28951311). The blockage of the PDCD1-mediated pathway results in the reversal of the exhausted T-cell phenotype and the normalization of the anti-tumor response, providing a rationale for cancer immunotherapy (PubMed : 22658127, PubMed : 25034862, PubMed : 25399552).
See full target information PDCD1

Publications (1)

Recent publications for all applications. Explore the full list and refine your search

Journal of biochemical and molecular toxicology 36:e23196 PubMed35979984

2022

PEX1 is a mediator of α1-adrenergic signaling attenuating doxorubicin-induced cardiotoxicity.

Applications

Unspecified application

Species

Unspecified reactive species

Wenjuan Li,Huilin Xie,Huang Hu,Jihong Huang,Sun Chen
View all publications

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com